Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL278329 | 0.89 | CDK1 (0.63) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL278330 | 0.87 | CDK1 (0.54) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27835776 | 0.84 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL26185797 | 0.84 | CDK1 (0.69) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL8994672 | 0.83 | CDK1 (0.67) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27667174 | 0.83 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL6666213 | 0.83 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL20746468 | 0.82 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL17165136 | 0.82 | CDK1 (0.69) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL19668079 | 0.81 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190269780-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ARS PHARMACEUTICALS INC. | 2019-09-05 | — | — | US | disclosed |
| US-8349353-B2 | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090324552-A1 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269780-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | CDK1 4857/4885CCNB1 4816/4885CA2 4062/4885 |
| US-20090324552-A1 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, SLC47A2, SLC26A4 | CDK1 2000/4885CCNB1 1177/4885CA2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.